EP Patent

EP1050301A1 — Medicinal compositions

Assigned to Tanabe Pharma Corp · Expires 2000-11-08 · 26y expired

What this patent protects

The present invention provides a pharmaceutical composition containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof, and cyclodextrin as a stabilizer, and where necessary, saccharide, which can be prepared into a l…

USPTO Abstract

The present invention provides a pharmaceutical composition containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof, and cyclodextrin as a stabilizer, and where necessary, saccharide, which can be prepared into a liquid agent, and which is useful for the suppression of rejection in organ or bone marrow transplantation, immunosuppressive sustention therapy therefor or the treatment of autoimmune diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP1050301A1
Jurisdiction
EP
Classification
Expires
2000-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.